WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2003076567) HETEROLOGOUS G-CSF FUSION PROTEINS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2003/076567    International Application No.:    PCT/US2003/003120
Publication Date: 18.09.2003 International Filing Date: 21.02.2003
IPC:
A61K 39/00 (2006.01), C07K 17/00 (2006.01), C07K 19/00 (2006.01)
Applicants: ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center, Indianapolis, IN 46285 (US) (For All Designated States Except US).
BEALS, John, Michael [US/US]; (US) (For US Only).
KUCHIBHOTLA, Uma [IN/US]; (US) (For US Only)
Inventors: BEALS, John, Michael; (US).
KUCHIBHOTLA, Uma; (US)
Agent: STEWART, Mark, J.; ELI LILLY AND COMPANY, P. O. Box 6288, Indianapolis, IN 47206-6288 (US)
Priority Data:
60/361,948 05.03.2002 US
Title (EN) HETEROLOGOUS G-CSF FUSION PROTEINS
(FR) PROTEINES HYBRIDES G-CSF HETEROLOGUES
Abstract: front page image
(EN)The present invention encompasses heterologous fusion proteins comprising a hyperglycsoylated G-CSF analog fusedto proteins such as albumin and the Fc portion of animmunoglobulin which act to extend the in vivo half-life ofthe protein compared to native G-CSF. These fusion proteinsare particularly suited for the treatment of conditions treatable by stimulation of circulating neutrophils, such as after chemotherapy regimens or in chronic congenitalneutropenia.
(FR)La présente invention concerne des protéines hybrides hétérologues, parmi lesquelles une protéine analogue G-CSF hyperglycosilée hybridée, lesquelles sont hybridées à des protéines telles que l'albumine et la portion Fc d'une immunoglobuline, ayant pour fonction d'allonger la demi-vie biologique in vivo de la protéine par rapport à la G-CSF d'origine. Ces protéines hybrides conviennent tout particulièrement au traitement de troubles nécessitant une stimulation de la circulation des neutrophiles, par exemple, après des traitements par chimiothérapie ou dans le cas d'une neutropénie congénitale chronique.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)